EMA agrees on "black triangle" for new drugs launched in EU
This article was originally published in SRA
All new products launched in the EU will have to display a black inverted triangle on their product information to denote that the product is subject to additional monitoring if the European Commission accepts the advice of the European Medicines Agency’s new pharmacovigilance committee, the PRAC1.
You may also be interested in...
The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.
Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.